Drug news

AUSTRI study of Advair Diskus, (LABA, salmeterol and fluticasone propionate) in asthma published in New England Journal of Medicine- GlaxoSmithKline

Read time: 1 mins

Last updated:8th Mar 2016

Published:8th Mar 2016

Source: Pharmawand

GlaxoSmithKline announced publication of results from the safety study, AUSTRI (SAS115359) in the New England Journal of Medicine (NEJM). The study, which reported results in October, compared Advair Diskus (LABA, salmeterol and fluticasone propionate) to fluticasone propionate (FP) monotherapy, to assess the safety profiles of each medicine when used to treat adolescent and adult patients with asthma.

This was assessed by the composite endpoint of serious asthma-related events (deaths, intubations or hospitalisations) and showed that Advair had a safety profile comparable to FP, including no asthma-related deaths in either arm. These results are being simultaneously presented at the American Academy of Asthma, Allergy and Immunology Congress in Los Angeles, California.

Learning Zone Homepage

Respiratory Care

The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves Alecensa (alectinib) as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Roche announced that the FDA has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours greater than 4 cm or node positive), as detected by an FDA-approved test

2 mins

Drug news

Iomab-B (apamistamab) to overcome high-risk TP53 mutation resulting in significant improvement in overall survival in patients with active relapsed refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. announced that results from the Phase III SIERRA trial of Iomab-B (apamistamab) were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17

1 min

Drug news

FDA approves Selarsdi (ustekinumab-biosimilar) to treat plaque psoriasis and active psoriatic arthritis

Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the FDA has approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older

2 min

See all news